USANA Health Sciences, Inc.
USNA · NYSE
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 2.44 | 0.12 | -0.65 |
| FCF Yield | -0.99% | 1.25% | 2.40% | 0.58% |
| EV / EBITDA | 33.00 | 14.82 | 13.60 | 32.94 |
| Quality | ||||
| ROIC | -0.75% | 1.51% | 1.38% | 0.55% |
| Gross Margin | 73.45% | 75.44% | 75.64% | 80.08% |
| Cash Conversion Ratio | 0.29 | 1.17 | 1.67 | 1.29 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.55% | -1.74% | -3.47% | -5.06% |
| Free Cash Flow Growth | -171.74% | -43.28% | 218.33% | -85.32% |
| Safety | ||||
| Net Debt / EBITDA | -12.74 | -5.28 | -5.72 | -8.67 |
| Interest Coverage | 24.98 | 64.55 | 38.13 | 63.64 |
| Efficiency | ||||
| Inventory Turnover | 0.62 | 0.70 | 0.83 | 0.61 |
| Cash Conversion Cycle | 116.89 | 101.56 | 88.22 | 125.61 |